Literature DB >> 11053909

A randomized prospective study of oral versus intravenous antibiotic prophylaxis against postoperative infection after sagittal split ramus osteotomy of the mandible.

T Yoda1, E Sakai, K Harada, M Mori, I Sakamoto, S Enomoto.   

Abstract

BACKGROUND: We investigated whether oral levofloxacin was as effective as intravenous cefazolin sodium for preventing postoperative infections in patients undergoing sagittal split ramus osteotomy of the mandible.
METHODS: Forty-four patients were randomized to treatment with levofloxacin or cefazolin sodium. Levofloxacin (100 mg t.d.s.) was administered orally, and cefazolin sodium (1 g b.i.d.) by intravenous infusion. Both drugs were given until 5 days postoperatively. The concentrations of levofloxacin in the mandibular bone marrow and serum were measured.
RESULTS: The mean levofloxacin concentration 4 h and 53.7 min after administration was 1.086 microg/ml in serum and 1.328 microg/ml in the mandibular bone marrow. The efficacy rate of levofloxacin was 95% and that of cefazolin sodium was 85.7%, with no significant difference between the two drugs (p = 0.322).
CONCLUSION: Oral administration of levofloxacin is a simple, cost-effective and safe alternative to intravenous antibiotic prophylaxis after mandibular surgery. Copyright 2000 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11053909     DOI: 10.1159/000007312

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  2 in total

1.  Antibiotic prophylaxis in foot and ankle surgery: a systematic review of the literature.

Authors:  Mr Ravi Krishān Modha; Chris Morriss-Roberts; Madeleine Smither; Jonathan Larholt; Ian Reilly
Journal:  J Foot Ankle Res       Date:  2018-11-15       Impact factor: 2.303

2.  Clinical Efficacy and Safety Analysis of Levofloxacin for the Prevention of Infection after Traumatic Osteoarthrosis and Internal Fixation: Systematic Review and Meta-Analysis.

Authors:  Weiliang Wang; ChuanQi Zou; Jie Zhang
Journal:  Emerg Med Int       Date:  2022-09-29       Impact factor: 1.621

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.